Document Detail

The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada.
MedLine Citation:
PMID:  23322588     Owner:  NLM     Status:  Publisher    
BACKGROUND: Cost-effectiveness evidence is increasingly considered in the reimbursement decisions of pharmaceuticals. In some jurisdictions such as the UK and Canada, pharmaceutical manufacturers are required to submit economic evaluations when seeking reimbursement. OBJECTIVES: Our objectives were to describe the role of economic evidence in the cancer drug review process in Canada, and to investigate the nature of problems encountered in the review and interpretation of economic evidence used in the process. DESIGN: We conducted a retrospective review of cancer drug review meeting minutes and reviewers' comments on pharmacoeconomic studies submitted to the oncology drug review process in Canada. DATA SOURCES: We used pharmacoeconomic reviewers' reports and relevant cancer drug review expert advisory committee meeting minutes during the first year of the review process (April 2007 to March 2008). RESULTS: Fifteen economic submissions were reviewed. One-third of the studies had flaws significant enough that the advisory committee could not determine the cost effectiveness of the drugs from the results. The common issues outlined by the reviewers and committee were related to the uncertainty of comparative clinical benefits, quality of life and costs. The reviewers felt that few analyses provided sufficient sensitivity analyses around key variables to assess the robustness of results. Most problems identified by reviewers are simple to fix and do not involve advanced methods. CONCLUSIONS: Canada has a separate review process for making cancer drug funding recommendations, and this process uses both clinical and economic evidence. The committee could not determine the value for money of the drugs from several of the submitted pharmacoeconomic analyses. Transparent analyses and detailed critique of evidence are crucial to the use of economic evidence in reimbursement decisions. Rigorous evaluation is resource intensive and may benefit from a shared drug review process among several jurisdictions.
Jean H E Yong; Jaclyn Beca; Jeffrey S Hoch
Related Documents :
24452808 - Encapsulation of poorly soluble drugs in polymer-drug conjugates: effect of dual-drug n...
23763998 - Mind the iqgap.
24513318 - Controlled release of doxorubicin from graphene oxide based charge-reversal nanocarrier.
19038618 - Update on the mechanism of action of topical prostaglandins for intraocular pressure re...
2841378 - Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-a on ...
2284568 - Contributions to the study of the favouring role of chronic urinary infections in induc...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-16
Journal Detail:
Title:  PharmacoEconomics     Volume:  -     ISSN:  1179-2027     ISO Abbreviation:  Pharmacoeconomics     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9212404     Medline TA:  Pharmacoeconomics     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version) : Consensus and Compr...
Next Document:  Low-frequency component of rectified EMG is temporally correlated with force and instantaneous rate ...